Jesús
San Miguel Izquierdo
Consultor Investigador
Instituto de Salud Carlos III
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (7)
2021
-
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma
Blood, Vol. 137, Núm. 1, pp. 49-60
-
Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial
Blood Advances, Vol. 5, Núm. 3, pp. 760-770
-
Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma
Cancers, Vol. 13, Núm. 19
2020
-
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Blood, Vol. 136, Núm. 2, pp. 199-209
2018
2000
-
Intra-muscular vidarabine therapy for polyomavirus-associated hemorrhagic cystitis following allogeneic hemopoietic stem cell transplantation
Bone Marrow Transplantation, Vol. 26, Núm. 11, pp. 1229-1230